

## IV-8. 甲状腺癌

CQ8-5 切除不能・再発甲状腺癌に対して分子標的薬は推奨されるか？

検索日：2021年3月20日(土)

No.	検索式	検索件数
#01	"Thyroid Neoplasms/drug therapy"[Mesh]	2,815
#02	"Iodine Radioisotopes/therapeutic use"[Mesh]	11,256
#03	"Molecular Targeted Therapy"[Mesh] OR "Immunoconjugates"[Mesh] OR "Sorafenib"[Mesh] OR "lenvatinib" [Supplementary Concept]	46,802
#04	#1 AND #2 AND #3	67
#05	thyroid[TI] AND (neoplasm*[TI] OR cancer*[TI] OR carcinoma*[TI] OR tumo*[TI])AND (advanced[TIAB] OR metasta*[TIAB] OR progressi*[TIAB]) AND ("radioactive iodine"[TI] OR RAI[TI] OR radioiodine[TI]) AND (molecular target*[TIAB] OR lenvatinib[TIAB] OR sorafenib[TIAB])	96
#06	#4 OR #5	129
#07	#6 AND 2000:2021[DP]	128
#08	#7 AND (JAPANESE[LA] OR ENGLISH[LA])	126
#09	#8 AND ("Meta-Analysis"[PT] OR "Meta-Analysis as Topic"[Mesh] OR "meta-	6
#10	#8 AND ("Cochrane Database Syst Rev"[TA] OR "Systematic Review"[PT] OR "Systematic Reviews as Topic"[Mesh] OR "systematic review"[TIAB])	6
#11	#8 AND ("Practice Guideline"[PT] OR "Practice Guidelines as Topic"[Mesh] OR "Consensus"[Mesh] OR "Consensus Development Conferences as Topic"[Mesh] OR "Consensus Development Conference"[PT] OR guideline*[TI] OR consensus[TI])	3
#12	#9 OR #10 OR #11	11
#13	#8 AND ("Randomized Controlled Trial"[PT] OR "Randomized Controlled Trials as Topic"[Mesh] OR (random*[TIAB] NOT medline[SB]))	20
#14	#8 AND ("Clinical Trial"[PT] OR "Clinical Trials as Topic"[Mesh] OR "Observational Study"[PT] OR "Observational Studies as Topic"[Mesh] OR ((clinical trial*[TIAB] OR case control*[TIAB] OR case comparison*[TIAB]) NOT medline[SB]))	40
#15	(#13 OR #14) NOT #12	40
#16	#8 AND ("Epidemiologic Methods"[Mesh] OR "Comparative Study"[PT] OR "Multicenter Study"[PT] OR ("survival analysis"[TIAB] OR cohort*[TIAB] OR comparative stud*[TIAB] OR follow-up stud*[TIAB] OR prospective stud*[TIAB] OR Retrospective study*[TIAB]) NOT medline[SB]))	59
#17	#16 NOT (#12 OR #15)	22